New Zealand Formulary
Menu Close Menu

Fewer cancers.
Better survival.
Equity for all.

Systemic Anti-Cancer Therapy Regimen Library

Home > LEU CML - pONATinib

LEU CML - pONATinib

Treatment Overview

Cardiovascular risk factor assessment is recommended—consult prescribing information for details.

Cycle 1 (and all further cycles) - 30 days

Cycle length:
30

Chronic phase CML: Consider a lower starting dose of 30 mg orally ONCE daily.


Consider dose reduction upon achievement of complete cytogenetic response.

Cycle details

Cycle 1 (and all further cycles) - 30 days

Medication Dose Route Days Max Duration
pONATinib 45 mg Once daily oral administration 1 to 30

Chronic phase CML: Consider a lower starting dose of 30 mg orally ONCE daily.


Consider dose reduction upon achievement of complete cytogenetic response.

Full details

Cycle 1 (and all further cycles) - 30 days

Day: 1

Medication Dose Route Max duration Details
pONATinib 45 mg Once daily oral administration
Instructions:
Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 2

Medication Dose Route Max duration Details
pONATinib 45 mg Once daily oral administration
Instructions:
Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 3

Medication Dose Route Max duration Details
pONATinib 45 mg Once daily oral administration
Instructions:
Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 4

Medication Dose Route Max duration Details
pONATinib 45 mg Once daily oral administration
Instructions:
Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 5

Medication Dose Route Max duration Details
pONATinib 45 mg Once daily oral administration
Instructions:
Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 6

Medication Dose Route Max duration Details
pONATinib 45 mg Once daily oral administration
Instructions:
Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 7

Medication Dose Route Max duration Details
pONATinib 45 mg Once daily oral administration
Instructions:
Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 8

Medication Dose Route Max duration Details
pONATinib 45 mg Once daily oral administration
Instructions:
Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 9

Medication Dose Route Max duration Details
pONATinib 45 mg Once daily oral administration
Instructions:
Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 10

Medication Dose Route Max duration Details
pONATinib 45 mg Once daily oral administration
Instructions:
Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 11

Medication Dose Route Max duration Details
pONATinib 45 mg Once daily oral administration
Instructions:
Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 12

Medication Dose Route Max duration Details
pONATinib 45 mg Once daily oral administration
Instructions:
Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 13

Medication Dose Route Max duration Details
pONATinib 45 mg Once daily oral administration
Instructions:
Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 14

Medication Dose Route Max duration Details
pONATinib 45 mg Once daily oral administration
Instructions:
Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 15

Medication Dose Route Max duration Details
pONATinib 45 mg Once daily oral administration
Instructions:
Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 16

Medication Dose Route Max duration Details
pONATinib 45 mg Once daily oral administration
Instructions:
Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 17

Medication Dose Route Max duration Details
pONATinib 45 mg Once daily oral administration
Instructions:
Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 18

Medication Dose Route Max duration Details
pONATinib 45 mg Once daily oral administration
Instructions:
Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 19

Medication Dose Route Max duration Details
pONATinib 45 mg Once daily oral administration
Instructions:
Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 20

Medication Dose Route Max duration Details
pONATinib 45 mg Once daily oral administration
Instructions:
Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 21

Medication Dose Route Max duration Details
pONATinib 45 mg Once daily oral administration
Instructions:
Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 22

Medication Dose Route Max duration Details
pONATinib 45 mg Once daily oral administration
Instructions:
Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 23

Medication Dose Route Max duration Details
pONATinib 45 mg Once daily oral administration
Instructions:
Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 24

Medication Dose Route Max duration Details
pONATinib 45 mg Once daily oral administration
Instructions:
Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 25

Medication Dose Route Max duration Details
pONATinib 45 mg Once daily oral administration
Instructions:
Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 26

Medication Dose Route Max duration Details
pONATinib 45 mg Once daily oral administration
Instructions:
Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 27

Medication Dose Route Max duration Details
pONATinib 45 mg Once daily oral administration
Instructions:
Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 28

Medication Dose Route Max duration Details
pONATinib 45 mg Once daily oral administration
Instructions:
Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 29

Medication Dose Route Max duration Details
pONATinib 45 mg Once daily oral administration
Instructions:
Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 30

Medication Dose Route Max duration Details
pONATinib 45 mg Once daily oral administration
Instructions:
Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Supportive Care Factors

Factor Value
Emetogenicity: Minimal to low
Tumour lysis syndrome prophylaxis: Tumour lysis syndrome prophylaxis may be considered

Antiviral prophylaxis for hepatitis B virus: Guidance is limited to high-risk anti-cancer medicines. Clinicians will need to assess individual patient risk for other anti-cancer medicines.

References

Jain, P., H. Kantarjian, E. Jabbour, et al. 2015. "Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study." Lancet Haematol 2(9):e376-383., PMID: 26436130

Cortes, J. E., H. Kantarjian, N. P. Shah, et al. 2012. "Ponatinib in refractory Philadelphia chromosome-positive leukemias." N Engl J Med 367(22):2075-2088., PMID: 23190221

Cortes, J. E., D. W. Kim, J. Pinilla-Ibarz, et al. 2013. "A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias." N Engl J Med 369(19):1783-1796. , PMID: 24180494

Lipton, J. H., C. Chuah, A. Guerci-Bresler, et al. 2016. "Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial." Lancet Oncol. , PMID: 27083332

Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Saußele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2. Epub 2020 Mar 3, PMID: 32127639

ARIAD Pharmaceuticals (Australia) Pty Ltd Iclusig Australian Product Information sheet 26 November 2014 https://www.tga.gov.au/sites/default/files/auspar-ponatinib-20150416-pi.pdf (Accessed 29 March 2022).

* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.

s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.